Carbonitriles as Inhibitors
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 19 5919
hibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett.
2000, 10, 945-949. (c) Widler, L.; Green, J.; Missbach, M.; Susa,
M.; Altmann, E. 7-Alkyl- and 7-cycloalkyl-5-arylpyrrolo[2,3-d]-
pyrimidines, potent inhibitors of the tyrosine kinase c-src.
Bioorg. Med. Chem. Lett. 2001, 11, 849-852. (d) Altmann, E.;
Missbach, M.; Green, J.; Susa, M.; Wagenknecht, H.-A.; Widler,
L. 7-Pyrrolidinyl- and 7-piperidinyl-5-arylpyrrolo[2,3-d]pyrim-
idines, potent inhibitors of the tyrosine kinase c-src. Bioorg. Med.
Chem. Lett. 2001, 11, 853-856. (e) Sundaramoorthi, R.; Shakes-
peare, W. C.; Keenan, T. P.; Metcalf, C. A., III; Wang, Y.; Mani,
U.; Taylor, M.; Liu, S.; Bohacek, R. S.; Narula, S. S.; Dalgarno,
D. C.; van Schravandijk, M. R.; Violette, S. M.; Liou, S.; Adams,
S.; Ram, M. K.; Keats, J. A.; Weigele, M.; Sawyer, T. K. Bioorg.
Med. Chem. Lett. 2003, 13, 3063-3066.
Biological Materials and Methods. Lysate preparation
was carried out as previously described.15b
Antibodies. The 4G10 antibody to phosphotyrosine, mono-
clonal antibody to Src (GD11), and cortactin were obtained
from Upstate Biotechnologies. Antibodies to focal adhesion
kinase (FAK), PY925 FAK, PY421 cortactin, and PY418 Src
were obtained from BioSource.
Acknowledgment. The authors acknowledge the
Wyeth Analytical Chemistry Department for providing
the spectral data, and Carlo Etienne for in vivo technical
assistance. Additionally, we thank Dr. Tarek Mansour
for his support.
(10) Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.;
Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A.
Discovery of a novel, potent, and Src family-selective tyrosine
kinase inhibitor. Study of Lck- and FynT-dependent T cell
activation. J. Biol. Chem. 1996, 271, 695-701.
(11) Guan, H.; Laird, A. D.; Blake, R. A.; Tang, C.; Liang, C. Design
and synthesis of aminopropyl tetrahydroindole-based indolin-
2-ones as selective and potent inhibitors of Src and Yes tyrosine
kinase. Bioorg. Med. Chem. Lett. 2004, 14, 187-190.
Supporting Information Available: Elemental analysis
data for compounds 4-15, 16a-i, and 17a-k. This material
is available free of charge via the Internet at http://
pubs.acs.org.
References
(12) (a) Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.;
Sawyers, C. L. Overriding imatinib resistance with a novel Abl
kinase inhibitor. Science 2004, 305, 399-401. (b) Lombardo, L.
J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.;
Castaneda, S.; Cornelius, L. A. M.; Das, J.; Doweyko, A. M.;
Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.;
Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.;
Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M.-L.; Wityak,
J.; Borzilleri, R. M. Discovery of N-(2-chloro-6-methyl-phenyl)-
2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-
ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl
kinase inhibitor with potent antitumor activity in preclinical
assays. J. Med. Chem. 2004, 47, 6658-6661.
(1) Schwartzberg, P. L. The many faces of Src: multiple functions
of a prototypical tyrosine kinase. Oncogene 1998, 17, 1463-1468.
(2) Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src
family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13, 513-609.
(3) Tsygankov, A. Y.; Shore, S. K. SRC: Regulation, role in human
carcinogenesis and pharmacological inhibitors. Curr. Pharm.
Des. 2004, 10, 1745-1756.
(4) (a) Mukhopadhyay, D.; Tsiokas, L.; Zhou, X. M.; Foster, D.;
Brugge, J. S.; Sukhatme, V. P. Hypoxic induction of human
vascular endothelial growth factor expression through c-Src
activation. Nature 1995, 375, 577-581. (b) Schlessinger, J. New
roles for Src kinases in control of cell survival and angiogenesis.
Cell 2000, 100, 293-296.
(13) Boschelli, D. H.; Powell, D.; Golas, J. M.; Boschelli, F. Inhibition
of Src kinase activity by 4-anilino-5,10-dihydropyrimido[4,5-b]-
quinolines. Bioorg. Med. Chem. Lett. 2003, 13, 2977-2980.
(14) Ple, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennell,
M.l; Allen, J.; Lambert-van der Brempt, C.; Costello, G. Discov-
ery of a new class of anilinoquinazoline inhibitors with high
affinity and specificity for the tyrosine kinase domain of c-Src.
J. Med. Chem. 2004, 47, 871-887.
(5) (a) Missbach, M.; Altmann, E.; Susa, M. Tyrosine kinase
inhibition in bone metabolism. Curr. Opin. Drug Discovery Dev.
2000, 3, 541-548. (b) Susa, M.; Teti, A. Tyrosine kinase Src
inhibitors: potential therapeutic applications. Drug News Per-
spect. 2000, 13, 169-175.
(6) Paul, R.; Zhang, Z. G.; Eliceiri, B. P.; Jiang, Q.; Boccia, A. D.;
Zhang, R. L.; Chopp, M.; Cheresh, D. A. Adhesion events in
angiogenesis. Nat. Med. 2001, 7, 222-227.
(7) (a) Wang, Y.; Metcalf, C. A., III; Shakespeare, W. C.; Sundar-
amoorthi, R.; Keenan, T. P.; Bohacek, R. S.; van Schravandijk,
M. R.; Violette, S. M.; Narula, S. S.; Dalgarno, D. C.; Haraldson,
C.; Keats, J.; Liou, S.; Mani, U.; Pradeepan, S.; Ram, M.; Adams,
S.; Weigele, M.; Sawyer, T. K. Bone-targeted 2,6,9-trisubstituted
purines: novel inhibitors of Src tyrosine kinase for the treatment
of bone diseases. Bioorg. Med. Chem. Lett. 2003, 13, 3067-3070.
(b) Wang, Y.; Lianping, X.; Metcalf, C. A.; Shakespeare, W.;
Sundaramoorthi, R.; Bohacek, R.; Narula, S.; Wardwell, S.;
Iuliucci, J.; Weigele, M.; Dalgarno, D.; Boyce, B.; Sawyer, T.
Signal transduction pathways and bone diseases: novel bone-
targeted Src kinase inhibitors with dual antiresorptive and bone
anabolic properties. Abstracts of Papers, 227th National Meeting
of the American Chemical Society, Anaheim, CA, March 28
through April 1, 2004; American Chemical Society: Washington,
DC, 2004; MEDI-346. (c) Sundaramoorthi, R.; Shakespeare, W.
C.; Metcalf, C. A.; Wang, Y.; Liu, S.; Bohacek, R. S.; Narula, S.
S.; Keats, J. A.; Wardwell, S.; Iuliucci, J.; Weigele, M.; Dalgarno,
Sawyer, T. K. Design and synthesis of novel bone-targeted Src
tyrosine kinase inhibitor drug discovery. Abstracts of Papers,
227th National Meeting of the American Chemical Society,
Anaheim, CA, March 28 through April 1, 2004; American
Chemical Society: Washington, DC, 2004; MEDI-038.
(8) (a) Klutchko, S. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.;
Kraker, A. J.; Amar, A. M.; Hartl, B. G.; Shen, C.; Klohs, W. D.;
Steinkampf, R. W.; Driscoll, D. L.; Nelson, J. M.; Elliott, W. L.;
Roberts, B. J.; Stoner, C. L.; Vincent, P. W.; Dykes, D. J.; Panek,
R. L.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Hallak, H.;
Bradford, L. A.; Showalter, H. D. H.; Doherty, A. M. 2-Substi-
tuted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activ-
ity relationships against selected tyrosine kinases and in vitro
and in vivo anticancer activity. J. Med. Chem. 1998, 41, 3276-
3292. (b) Kraker, A. J.; Hartl, B. G.; Amar, A. M.; Barvian, M.
R.; Showalter, H. D. H.; Moore, C. W. Biochemical and cellular
effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine
kinase inhibitors. Biochem. Pharmacol. 2000, 60, 885-898.
(9) (a) Missbach, M.; Jeschke, M.; Feyen, J.; Muller, K.; Glatt, M.;
Green, J.; Susa, M. A novel inhibitor of the tyrosine kinase Src
suppresses phosphorylation of its major cellular substrates and
reduces bone resorption in vitro and in rodent models in vivo.
Bone 1999, 24, 437-449. (b) Missbach, M.; Altmann, E.; Widler,
L.; Susa, M.; Buchdunger, E.; Mett, H.; Meyer, T.; Green, J.
Substituted 5,7-diphenylpyrrolo[2,3-d]pyrimidines: potent in-
(15) (a) Wang, Y. D.; Miller, K.; Boschelli, D. H.; Ye, F.; Wu, B.; Floyd,
M. B.; Powell, D. W.; Wissner, A.; Weber, J. M.; Boschelli, F.
Inhibitors of Src tyrosine kinase: the preparation and structure-
activity relationship of 4-anilino-3-cyanoquinolines and 4-anili-
noquinazolines. Bioorg. Med. Chem. Lett. 2000, 10, 2477-2480.
(b) Boschelli, D. H.; Wang, Y. D.; Ye, F.; Wu, B.; Zhang, N.; Dutia,
M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J. M.; Boschelli,
F. Synthesis and Src kinase inhibitory activity of a series of
4-phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 2001, 44,
822-833. (c) Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.;
Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.;
Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.;
Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F.
Optimization of 4-phenylamino-3-quinolinecarbonitriles as po-
tent inhibitors of Src kinase activity. J. Med. Chem. 2001, 44,
3965-3977. (d) Boschelli, D. H.; Wang, D. Y.; Ye, F.; Yamashita,
A.; Zhang, N.; Powell, D.; Weber, J.; Boschelli, F. Inhibition of
Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarboni-
triles. Bioorg. Med. Chem. Lett. 2002, 12, 2011-2014. (e) Berger,
D.; Dutia, M.; Powell, D.; Wissner, A.; DeMorin, F.; Raifeld, Y.;
Weber, J.; Boschelli, F. Substituted 4-anilino-7-phenyl-3-quino-
linecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem.
Lett. 2002, 12, 2989-2992. (f) Boschelli, D. H.; Ye, F.; Wu, B.;
Wang, Y. D.; Barrios Sosa, A. C.; Yaczko, D.; Powell, D.; Golas,
J. M.; Lucas, J.; Boschelli, F. Investigation of the effect of varying
the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on
the inhibition of Src kinase activity. Bioorg. Med. Chem. Lett.
2003, 13, 3797-3800. (g) Golas, J. M.; Arndt, K.; Etienne, C.;
Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli,
D. H.; Boschelli, F. SKI-606, a 4-anilino-3-quinolinecarbonitrile
dual inhibitor of Src and Abl kinases, is a potent antiproliferative
agent against chronic myelogenous leukemia cells in culture and
causes regression of K562 xenografts in nude mice. Cancer Res.
2003, 63, 375-381. (h) Barrios Sosa, A. C.; Boschelli, D. H.; Ye,
F.; Golas, J. M.; Boschelli, F. Synthesis and inhibition of Src
kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinoli-
necarbonitriles. Bioorg. Med. Chem. Lett. 2004, 14, 2155-2158.
(i) Boschelli, D. H.; Wang, Y. D.; Johnson, S.; Wu, B.; Ye, F.;
Barrios Sosa, A. C.; Golas, J. M.; Boschelli, F. 7-Alkoxy-4-
phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src
and Abl kinases. J. Med. Chem. 2004, 47, 1599-1601. (j) Barrios